B. Riley Reaffirms "Buy" Rating for Harrow Health (NASDAQ:HR

B. Riley reaffirmed their buy rating on shares of Harrow Health (NASDAQ:HROW – Get Rating) in a research note published on Thursday morning, PriceTargets.com reports. B. Riley also issued estimates for Harrow Health’s FY2026 earnings at $4.27 EPS and FY2027 earnings at $6.22 EPS. HROW has been the subject of several other reports. Lake Street […]

Related Keywords

, News Ratings For Harrow Health Daily , Dorsey Wright Associates , Northwestern Mutual Wealth Management Co , Surface Ophthalmics Inc , Tower Research Capital , Harrow Health Price Performance , Harrow Health , Harrow Health Inc , Hedge Funds Weigh In On Harrow Health , Barclays Plc , Pharmaceuticals Inc , Eton Pharmaceuticals Inc , Get Rating , Street Capital , Mutual Wealth Management , Research Capital , Captrust Financial Advisors , Surface Ophthalmics , Melt Pharmaceuticals , Eton Pharmaceuticals , Harrow Health Daily , Nasdaq Hrow , Throw , Medical , Reiterated Rating , B Riley ,